Acadia Healthcare to Participate in Three Investor Conferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Should l Buy ACHC?
Source: Newsfilter
- Conference Schedule: Acadia Healthcare will participate in three investor conferences in March 2026, including the Raymond James Annual Conference on March 2, the Leerink Partners Global Healthcare Conference on March 9, and the Barclays Global Healthcare Conference on March 10, showcasing the company's ongoing influence in the healthcare sector.
- Presentation Times: At the Raymond James conference, Acadia's presentation will start at 11:35 AM Eastern Time, followed by the Leerink Partners conference at 3:40 PM on March 9, and concluding with the Barclays conference at 12:00 PM on March 10, ensuring timely updates for investors.
- Live Webcast: All presentations will be available via live webcast on Acadia's website, where investors can click on the
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACHC
Wall Street analysts forecast ACHC stock price to fall
11 Analyst Rating
5 Buy
5 Hold
1 Sell
Moderate Buy
Current: 22.990
Low
13.00
Averages
18.10
High
25.00
Current: 22.990
Low
13.00
Averages
18.10
High
25.00
About ACHC
Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services across the United States. It provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics. Its acute inpatient psychiatric facilities provide a high level of care in order to stabilize patients that are either a threat to themselves or to others. Its specialty treatment facilities include residential recovery facilities and eating disorder facilities. Its comprehensive treatment centers specialize in providing medication-assisted treatment in an outpatient setting. Its residential treatment centers treat patients with behavioral disorders in a non-hospital setting. The facilities balance therapy activities with social, academic and other activities. It operates a network of 262 behavioral healthcare facilities with over 11,850 beds in 39 states and Puerto Rico.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Canyon Capital Advisors Exits Acadia Healthcare Position Completely
- Complete Exit: Canyon Capital Advisors fully exited its position in Acadia Healthcare by selling 521,774 shares in Q4 2026, resulting in a decrease of approximately $12.92 million in position value, indicating a pessimistic outlook on the company's future prospects.
- Poor Stock Performance: As of Tuesday, Acadia Healthcare's shares were priced at $22.74, down 22% over the past year, significantly underperforming the S&P 500, which rose about 16%, highlighting the company's lack of competitiveness in the market.
- Complex Financial Situation: Despite a 6.1% year-over-year revenue increase to $821.5 million in Q4, the company faced a $996.2 million goodwill impairment, leading to an adjusted EBITDA drop to $608.9 million, indicating operational pressures with a net leverage of 4.0x limiting financial flexibility.
- Uncertain Market Outlook: Canyon's exit suggests a preference for clearer asset-backed recovery plays over healthcare turnaround risks, prompting long-term investors to monitor occupancy trends and liability reserve stability to gauge future market sentiment shifts.
See More
Canyon Capital Fully Exits Acadia Healthcare Position
- Shareholding Change: Canyon Capital sold 521,774 shares of Acadia Healthcare in Q4, resulting in a decrease of approximately $12.92 million in position value, indicating a significant loss of confidence in the company.
- Financial Performance: Although Acadia Healthcare reported a 6.1% revenue increase to $821.5 million in Q4, the adjusted EBITDA fell to $608.9 million due to a $996.2 million goodwill impairment, highlighting the financial pressures the company faces.
- Market Environment: Acadia Healthcare's stock has declined about 20% over the past year, with a staggering drop of up to 60% in recent months, reflecting the company's vulnerability amid broader financial pressures, warranting caution from investors.
- Investment Strategy Shift: Canyon Capital's exit suggests a preference for asset-backed recovery plays over healthcare turnaround risks, necessitating close monitoring of Acadia's occupancy trends and liability reserve stability moving forward.
See More
Acadia Healthcare Receives Overweight Rating
- Rating Analysis: Acadia Healthcare (ACHC) has received an overweight rating, indicating analysts' optimistic expectations for its future performance, which may attract more investor attention.
- Price Target: The average price target set by analysts is $22, suggesting there is room for stock price appreciation, which could yield substantial returns for investors if achieved.
- Market Confidence: The overweight rating reflects market confidence in Acadia Healthcare's continued growth potential within the healthcare sector, potentially driving its stock price higher.
- Investment Appeal: With analysts' positive evaluations of Acadia Healthcare, it is expected to attract more institutional investors, further enhancing its market performance.
See More
Acadia Healthcare Q4 2025 Earnings Call Insights
- Leadership Transition: CEO Debra Osteen emphasized a renewed focus on stability and execution, planning to enhance company performance by reinforcing operational discipline and supporting field teams, aiming to lay a foundation for future success.
- Financial Performance Review: Q4 2025 revenue reached $821.5 million, a 6.1% year-over-year increase, with adjusted EBITDA at $99.8 million, reflecting a 4.4% growth in same-facility revenue driven by a 1.3% increase in revenue per patient day and a 3.1% rise in patient days.
- Future Outlook: The company expects 2026 revenue between $3.37 billion and $3.45 billion, with adjusted EBITDA projected at $575 million to $610 million, reflecting expectations for same-facility growth and anticipated start-up losses from new facilities.
- Capital Expenditure Management: Total capital expenditures for 2025 amounted to $572 million, below guidance, with management stressing that each project must demonstrate clear market fundamentals and patient needs to ensure effective capital utilization.
See More
U.S. Stocks Rise as TJX Reports Strong Earnings Beat
- Market Performance: U.S. stocks broadly rose on Wednesday, with the Nasdaq Composite gaining over 250 points, indicating improved market sentiment, particularly as technology shares increased by 1.6%, reflecting heightened investor confidence in the tech sector.
- TJX Earnings Report: TJX Companies reported fourth-quarter earnings of $1.43 per share, surpassing analyst expectations of $1.39, with sales reaching $17.743 billion, also exceeding the consensus estimate of $17.370 billion, showcasing the company's robust performance in retail.
- Future Outlook: Despite TJX's FY2027 GAAP EPS guidance of $4.93 to $5.02 falling short of the market estimate of $5.17, the strong quarterly results may still attract investor interest, reflecting the company's resilience in an uncertain market environment.
- Economic Data: The volume of mortgage applications in the U.S. increased by 0.4% in the third week of February, although this was lower than the previous week's 2.8% gain, indicating a gradual recovery in the housing market that could positively impact future economic growth.
See More
Acadia Healthcare Reports Strong Q4 Earnings Beat and Positive Guidance
- Earnings Beat: Acadia Healthcare reported fourth-quarter adjusted earnings of 7 cents per share, surpassing the consensus estimate of 6 cents, with sales reaching $821.46 million, exceeding the expected $800.07 million, indicating effective volume growth improvements.
- Significant Revenue Growth: The company experienced a 6.1% year-over-year sales increase in Q4, with same-facility revenue rising 4.4%, driven by a 3.1% increase in patient days and a 1.3% rise in revenue per patient day, despite a 2% drag from closed facilities over the past year.
- Optimistic Future Guidance: Acadia projects 2026 revenues between $3.37 billion and $3.45 billion, slightly below the consensus of $3.41 billion, while expecting adjusted earnings of $1.30 to $1.55 per share, reflecting a cautious optimism about future growth.
- Strong Stock Performance: As of Wednesday, Acadia Healthcare's stock rose 23.06% to $21.13, indicating a positive market reaction to its earnings and outlook, while technical analysis suggests strong short-term momentum.
See More
Canyon Capital Advisors Exits Acadia Healthcare Position Completely
- Complete Exit: Canyon Capital Advisors fully exited its position in Acadia Healthcare by selling 521,774 shares in Q4 2026, resulting in a decrease of approximately $12.92 million in position value, indicating a pessimistic outlook on the company's future prospects.
- Poor Stock Performance: As of Tuesday, Acadia Healthcare's shares were priced at $22.74, down 22% over the past year, significantly underperforming the S&P 500, which rose about 16%, highlighting the company's lack of competitiveness in the market.
- Complex Financial Situation: Despite a 6.1% year-over-year revenue increase to $821.5 million in Q4, the company faced a $996.2 million goodwill impairment, leading to an adjusted EBITDA drop to $608.9 million, indicating operational pressures with a net leverage of 4.0x limiting financial flexibility.
- Uncertain Market Outlook: Canyon's exit suggests a preference for clearer asset-backed recovery plays over healthcare turnaround risks, prompting long-term investors to monitor occupancy trends and liability reserve stability to gauge future market sentiment shifts.
See More
Canyon Capital Fully Exits Acadia Healthcare Position
- Shareholding Change: Canyon Capital sold 521,774 shares of Acadia Healthcare in Q4, resulting in a decrease of approximately $12.92 million in position value, indicating a significant loss of confidence in the company.
- Financial Performance: Although Acadia Healthcare reported a 6.1% revenue increase to $821.5 million in Q4, the adjusted EBITDA fell to $608.9 million due to a $996.2 million goodwill impairment, highlighting the financial pressures the company faces.
- Market Environment: Acadia Healthcare's stock has declined about 20% over the past year, with a staggering drop of up to 60% in recent months, reflecting the company's vulnerability amid broader financial pressures, warranting caution from investors.
- Investment Strategy Shift: Canyon Capital's exit suggests a preference for asset-backed recovery plays over healthcare turnaround risks, necessitating close monitoring of Acadia's occupancy trends and liability reserve stability moving forward.
See More
Acadia Healthcare Receives Overweight Rating
- Rating Analysis: Acadia Healthcare (ACHC) has received an overweight rating, indicating analysts' optimistic expectations for its future performance, which may attract more investor attention.
- Price Target: The average price target set by analysts is $22, suggesting there is room for stock price appreciation, which could yield substantial returns for investors if achieved.
- Market Confidence: The overweight rating reflects market confidence in Acadia Healthcare's continued growth potential within the healthcare sector, potentially driving its stock price higher.
- Investment Appeal: With analysts' positive evaluations of Acadia Healthcare, it is expected to attract more institutional investors, further enhancing its market performance.
See More
Acadia Healthcare Q4 2025 Earnings Call Insights
- Leadership Transition: CEO Debra Osteen emphasized a renewed focus on stability and execution, planning to enhance company performance by reinforcing operational discipline and supporting field teams, aiming to lay a foundation for future success.
- Financial Performance Review: Q4 2025 revenue reached $821.5 million, a 6.1% year-over-year increase, with adjusted EBITDA at $99.8 million, reflecting a 4.4% growth in same-facility revenue driven by a 1.3% increase in revenue per patient day and a 3.1% rise in patient days.
- Future Outlook: The company expects 2026 revenue between $3.37 billion and $3.45 billion, with adjusted EBITDA projected at $575 million to $610 million, reflecting expectations for same-facility growth and anticipated start-up losses from new facilities.
- Capital Expenditure Management: Total capital expenditures for 2025 amounted to $572 million, below guidance, with management stressing that each project must demonstrate clear market fundamentals and patient needs to ensure effective capital utilization.
See More
U.S. Stocks Rise as TJX Reports Strong Earnings Beat
- Market Performance: U.S. stocks broadly rose on Wednesday, with the Nasdaq Composite gaining over 250 points, indicating improved market sentiment, particularly as technology shares increased by 1.6%, reflecting heightened investor confidence in the tech sector.
- TJX Earnings Report: TJX Companies reported fourth-quarter earnings of $1.43 per share, surpassing analyst expectations of $1.39, with sales reaching $17.743 billion, also exceeding the consensus estimate of $17.370 billion, showcasing the company's robust performance in retail.
- Future Outlook: Despite TJX's FY2027 GAAP EPS guidance of $4.93 to $5.02 falling short of the market estimate of $5.17, the strong quarterly results may still attract investor interest, reflecting the company's resilience in an uncertain market environment.
- Economic Data: The volume of mortgage applications in the U.S. increased by 0.4% in the third week of February, although this was lower than the previous week's 2.8% gain, indicating a gradual recovery in the housing market that could positively impact future economic growth.
See More
Acadia Healthcare Reports Strong Q4 Earnings Beat and Positive Guidance
- Earnings Beat: Acadia Healthcare reported fourth-quarter adjusted earnings of 7 cents per share, surpassing the consensus estimate of 6 cents, with sales reaching $821.46 million, exceeding the expected $800.07 million, indicating effective volume growth improvements.
- Significant Revenue Growth: The company experienced a 6.1% year-over-year sales increase in Q4, with same-facility revenue rising 4.4%, driven by a 3.1% increase in patient days and a 1.3% rise in revenue per patient day, despite a 2% drag from closed facilities over the past year.
- Optimistic Future Guidance: Acadia projects 2026 revenues between $3.37 billion and $3.45 billion, slightly below the consensus of $3.41 billion, while expecting adjusted earnings of $1.30 to $1.55 per share, reflecting a cautious optimism about future growth.
- Strong Stock Performance: As of Wednesday, Acadia Healthcare's stock rose 23.06% to $21.13, indicating a positive market reaction to its earnings and outlook, while technical analysis suggests strong short-term momentum.
See More
